Gabriel Rinnerthaler

8PUBLICATIONS

40CO-AUTHORS

Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersHaematological tumours

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (8)

Sort by Publication Date:

|Jun 26, 2026

Reducing breast cancer recurrences with CDK4/6 inhibitor treatment of HR-positive, HER2-negative early stage breast cancer from a societal perspective.

|Mar 07, 2025

Augmenting Insufficiently Accruing Oncology Clinical Trials Using Generative Models: Validation Study.

Samer El Kababji, Nicholas Mitsakakis, Elizabeth Jonker

|Jan 17, 2025

Neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in women with early HER2-positive breast cancer: the randomized phase 2 ABCSG-52/ATHENE trial.

Gabriel Rinnerthaler, Daniel Egle, Rupert Bartsch

|Jan 11, 2022

Sex-Based Clinical Outcome in Advanced NSCLC Patients Undergoing PD-1/PD-L1 Inhibitor Therapy-A Retrospective Bi-Centric Cohort Study.

David Lang, Anna Brauner, Florian Huemer

|Dec 04, 2021

Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response.

Qing Zhou, Simon P Gampenrieder, Sophie Frantal

|Jun 02, 2021

Prognostic and Predictive Factors in Advanced Head and Neck Squamous Cell Carcinoma.

Teresa Magnes, Sandro Wagner, Dominik Kiem

Pageof 2

Frequent Collaborators

Richard Greil

Florian Huemer

Marija Balic

Michael Gnant

Teresa Magnes

Dominik Hlauschek

Daniel Egle

Zsuzsanna Bago-Horvath

2 joint publications

Martin Filipits

1 joint publications

Lukas Weiss

Frequent Collaborators

Richard Greil

Florian Huemer

Marija Balic

Michael Gnant